The two companies jointly announced their cooperation on the central nervous system (CNS) disease pipeline project. According to the terms of the agreement, Neushen will obtain global exclusive development rights, registration and commercialization rights for the project, involving indications such as epilepsy and emotional disorders. Based on this collaboration, HealZen Therapeutics will receive an upfront payment and R&D milestone payments.

Dr.Xinglu Zhou, co-founder and CEO of HealZen Therapeutics, said: "We are honored and delighted to cooperate with Neushen. HealZen has always been committed to the discovery of new therapeutic drugs based on the advanced technologies. This project is another case output from the small molecule drug development platform of HealZen. We believe that with its rich R&D experience in CNS treatment, Neushen will quickly advance the project into clinical development and bring positive therapeutic effects to patients in the near future."

"We are pleased to enter into this collaboration with HealZen," said Joan Huaqiong Shen, founder and CEO of Neushen. " We will continue the full range of pre-clinical research and development. We will formulate and execute our clinical development strategy based on the characteristics of the compound and the clinical needs of the target indication. This project will further strengthen our pipeline to target psychiatric disorders.”

As the global population structure changes and aging intensifies, CNS diseases have become major health and social problems faced by countries around the world. CNS disease affect a large number of patients and often have chronic characteristics, causing enormous pain and harm to patients. This project is an innovative drug developed independently by HealZen, showing unique advantages and good efficacy in various in vitro and in vivo CNS models, which is expected to become a potential new treatment for diseases such as epilepsy and emotional disorders.